Allogeneic transplantation using CD34+ selected peripheral blood progenitor cells combined with non-mobilized donor T cells for refractory severe aplastic anaemia

Enkhtsetseg Purev, Xin Tian, Georg Aue, Jeremy Mark Pantin, Phuong Vo, Reem Shalabi, Robert N. Reger, Lisa Cook, Catalina Ramos, Elena Cho, Tat'yana Worthy, Hanh Khuu, David Stroncek, Neal S. Young, Richard W. Childs

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Allogeneic haematopoietic stem cell transplantation is curative for severe aplastic anaemia (SAA) unresponsive to immunosuppressive therapy. To reduce chronic graft-versus-host disease (GVHD), which occurs more frequently after peripheral blood stem cell (PBSC) transplantation compared to bone-marrow transplantation (BMT), and to prevent graft rejection, we developed a novel partial T-cell depleted transplant that infuses high numbers of granulocyte colony-stimulating factor-mobilized CD34+ selected PBSCs combined with a BMT-equivalent dose of non-mobilized donor T-cells. Fifteen patients with refractory SAA received cyclophosphamide, anti-thymocyte globulin and fludarabine conditioning, and were transplanted with a median 8 × 106 CD34+ cells/kg and 2 × 107 non-mobilized CD3+ T-cells/kg from human leucocyte antigen-matched sibling donors. All achieved sustained engraftment with only two developing acute and two developing chronic GVHD. With a 3·5-year median follow-up, 86% of patients survived and were transfusion-independent. When compared to a retrospective cohort of 56 bone-marrow failure patients that received the identical transplant preparative regimen and GVHD prophylaxis with the exception that the allograft contained unmanipulated PBSCs, partial T-cell depleted transplant recipients had delayed donor T-cell chimerism and relative reduction of 75% in the incidence of acute grade II-IV GVHD (13% vs. 52%; P = 0·010) and of 82% in chronic GVHD (13% vs. 72%; P = 0·0004). In multivariate analysis, partial T-cell depleted transplants remained significantly associated with a reduced risk of GVHD. In conclusion, for patients with refractory SAA, this novel transplant strategy achieves excellent engraftment and survival when compared to unmanipulated PBSC transplants and dramatically reduces the incidence of both acute and chronic GVHD.

Original languageEnglish (US)
Pages (from-to)950-960
Number of pages11
JournalBritish Journal of Haematology
Volume176
Issue number6
DOIs
StatePublished - Mar 1 2017

Fingerprint

Aplastic Anemia
Homologous Transplantation
Graft vs Host Disease
Blood Cells
Stem Cells
Tissue Donors
T-Lymphocytes
Transplants
Bone Marrow Transplantation
Peripheral Blood Stem Cell Transplantation
Chimerism
Antilymphocyte Serum
Hematopoietic Stem Cell Transplantation
Incidence
Graft Rejection
Granulocyte Colony-Stimulating Factor
Immunosuppressive Agents
HLA Antigens
Cyclophosphamide
Allografts

Keywords

  • CD34 selected PBSC
  • allogeneic stem cell transplantation
  • bone marrow transplantation
  • partial T-cell depleted transplant
  • severe aplastic anaemia

ASJC Scopus subject areas

  • Hematology

Cite this

Allogeneic transplantation using CD34+ selected peripheral blood progenitor cells combined with non-mobilized donor T cells for refractory severe aplastic anaemia. / Purev, Enkhtsetseg; Tian, Xin; Aue, Georg; Pantin, Jeremy Mark; Vo, Phuong; Shalabi, Reem; Reger, Robert N.; Cook, Lisa; Ramos, Catalina; Cho, Elena; Worthy, Tat'yana; Khuu, Hanh; Stroncek, David; Young, Neal S.; Childs, Richard W.

In: British Journal of Haematology, Vol. 176, No. 6, 01.03.2017, p. 950-960.

Research output: Contribution to journalArticle

Purev, E, Tian, X, Aue, G, Pantin, JM, Vo, P, Shalabi, R, Reger, RN, Cook, L, Ramos, C, Cho, E, Worthy, T, Khuu, H, Stroncek, D, Young, NS & Childs, RW 2017, 'Allogeneic transplantation using CD34+ selected peripheral blood progenitor cells combined with non-mobilized donor T cells for refractory severe aplastic anaemia', British Journal of Haematology, vol. 176, no. 6, pp. 950-960. https://doi.org/10.1111/bjh.14448
Purev, Enkhtsetseg ; Tian, Xin ; Aue, Georg ; Pantin, Jeremy Mark ; Vo, Phuong ; Shalabi, Reem ; Reger, Robert N. ; Cook, Lisa ; Ramos, Catalina ; Cho, Elena ; Worthy, Tat'yana ; Khuu, Hanh ; Stroncek, David ; Young, Neal S. ; Childs, Richard W. / Allogeneic transplantation using CD34+ selected peripheral blood progenitor cells combined with non-mobilized donor T cells for refractory severe aplastic anaemia. In: British Journal of Haematology. 2017 ; Vol. 176, No. 6. pp. 950-960.
@article{288421dcc0534751afbee9306cbede47,
title = "Allogeneic transplantation using CD34+ selected peripheral blood progenitor cells combined with non-mobilized donor T cells for refractory severe aplastic anaemia",
abstract = "Allogeneic haematopoietic stem cell transplantation is curative for severe aplastic anaemia (SAA) unresponsive to immunosuppressive therapy. To reduce chronic graft-versus-host disease (GVHD), which occurs more frequently after peripheral blood stem cell (PBSC) transplantation compared to bone-marrow transplantation (BMT), and to prevent graft rejection, we developed a novel partial T-cell depleted transplant that infuses high numbers of granulocyte colony-stimulating factor-mobilized CD34+ selected PBSCs combined with a BMT-equivalent dose of non-mobilized donor T-cells. Fifteen patients with refractory SAA received cyclophosphamide, anti-thymocyte globulin and fludarabine conditioning, and were transplanted with a median 8 × 106 CD34+ cells/kg and 2 × 107 non-mobilized CD3+ T-cells/kg from human leucocyte antigen-matched sibling donors. All achieved sustained engraftment with only two developing acute and two developing chronic GVHD. With a 3·5-year median follow-up, 86{\%} of patients survived and were transfusion-independent. When compared to a retrospective cohort of 56 bone-marrow failure patients that received the identical transplant preparative regimen and GVHD prophylaxis with the exception that the allograft contained unmanipulated PBSCs, partial T-cell depleted transplant recipients had delayed donor T-cell chimerism and relative reduction of 75{\%} in the incidence of acute grade II-IV GVHD (13{\%} vs. 52{\%}; P = 0·010) and of 82{\%} in chronic GVHD (13{\%} vs. 72{\%}; P = 0·0004). In multivariate analysis, partial T-cell depleted transplants remained significantly associated with a reduced risk of GVHD. In conclusion, for patients with refractory SAA, this novel transplant strategy achieves excellent engraftment and survival when compared to unmanipulated PBSC transplants and dramatically reduces the incidence of both acute and chronic GVHD.",
keywords = "CD34 selected PBSC, allogeneic stem cell transplantation, bone marrow transplantation, partial T-cell depleted transplant, severe aplastic anaemia",
author = "Enkhtsetseg Purev and Xin Tian and Georg Aue and Pantin, {Jeremy Mark} and Phuong Vo and Reem Shalabi and Reger, {Robert N.} and Lisa Cook and Catalina Ramos and Elena Cho and Tat'yana Worthy and Hanh Khuu and David Stroncek and Young, {Neal S.} and Childs, {Richard W.}",
year = "2017",
month = "3",
day = "1",
doi = "10.1111/bjh.14448",
language = "English (US)",
volume = "176",
pages = "950--960",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Allogeneic transplantation using CD34+ selected peripheral blood progenitor cells combined with non-mobilized donor T cells for refractory severe aplastic anaemia

AU - Purev, Enkhtsetseg

AU - Tian, Xin

AU - Aue, Georg

AU - Pantin, Jeremy Mark

AU - Vo, Phuong

AU - Shalabi, Reem

AU - Reger, Robert N.

AU - Cook, Lisa

AU - Ramos, Catalina

AU - Cho, Elena

AU - Worthy, Tat'yana

AU - Khuu, Hanh

AU - Stroncek, David

AU - Young, Neal S.

AU - Childs, Richard W.

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Allogeneic haematopoietic stem cell transplantation is curative for severe aplastic anaemia (SAA) unresponsive to immunosuppressive therapy. To reduce chronic graft-versus-host disease (GVHD), which occurs more frequently after peripheral blood stem cell (PBSC) transplantation compared to bone-marrow transplantation (BMT), and to prevent graft rejection, we developed a novel partial T-cell depleted transplant that infuses high numbers of granulocyte colony-stimulating factor-mobilized CD34+ selected PBSCs combined with a BMT-equivalent dose of non-mobilized donor T-cells. Fifteen patients with refractory SAA received cyclophosphamide, anti-thymocyte globulin and fludarabine conditioning, and were transplanted with a median 8 × 106 CD34+ cells/kg and 2 × 107 non-mobilized CD3+ T-cells/kg from human leucocyte antigen-matched sibling donors. All achieved sustained engraftment with only two developing acute and two developing chronic GVHD. With a 3·5-year median follow-up, 86% of patients survived and were transfusion-independent. When compared to a retrospective cohort of 56 bone-marrow failure patients that received the identical transplant preparative regimen and GVHD prophylaxis with the exception that the allograft contained unmanipulated PBSCs, partial T-cell depleted transplant recipients had delayed donor T-cell chimerism and relative reduction of 75% in the incidence of acute grade II-IV GVHD (13% vs. 52%; P = 0·010) and of 82% in chronic GVHD (13% vs. 72%; P = 0·0004). In multivariate analysis, partial T-cell depleted transplants remained significantly associated with a reduced risk of GVHD. In conclusion, for patients with refractory SAA, this novel transplant strategy achieves excellent engraftment and survival when compared to unmanipulated PBSC transplants and dramatically reduces the incidence of both acute and chronic GVHD.

AB - Allogeneic haematopoietic stem cell transplantation is curative for severe aplastic anaemia (SAA) unresponsive to immunosuppressive therapy. To reduce chronic graft-versus-host disease (GVHD), which occurs more frequently after peripheral blood stem cell (PBSC) transplantation compared to bone-marrow transplantation (BMT), and to prevent graft rejection, we developed a novel partial T-cell depleted transplant that infuses high numbers of granulocyte colony-stimulating factor-mobilized CD34+ selected PBSCs combined with a BMT-equivalent dose of non-mobilized donor T-cells. Fifteen patients with refractory SAA received cyclophosphamide, anti-thymocyte globulin and fludarabine conditioning, and were transplanted with a median 8 × 106 CD34+ cells/kg and 2 × 107 non-mobilized CD3+ T-cells/kg from human leucocyte antigen-matched sibling donors. All achieved sustained engraftment with only two developing acute and two developing chronic GVHD. With a 3·5-year median follow-up, 86% of patients survived and were transfusion-independent. When compared to a retrospective cohort of 56 bone-marrow failure patients that received the identical transplant preparative regimen and GVHD prophylaxis with the exception that the allograft contained unmanipulated PBSCs, partial T-cell depleted transplant recipients had delayed donor T-cell chimerism and relative reduction of 75% in the incidence of acute grade II-IV GVHD (13% vs. 52%; P = 0·010) and of 82% in chronic GVHD (13% vs. 72%; P = 0·0004). In multivariate analysis, partial T-cell depleted transplants remained significantly associated with a reduced risk of GVHD. In conclusion, for patients with refractory SAA, this novel transplant strategy achieves excellent engraftment and survival when compared to unmanipulated PBSC transplants and dramatically reduces the incidence of both acute and chronic GVHD.

KW - CD34 selected PBSC

KW - allogeneic stem cell transplantation

KW - bone marrow transplantation

KW - partial T-cell depleted transplant

KW - severe aplastic anaemia

UR - http://www.scopus.com/inward/record.url?scp=85012095483&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85012095483&partnerID=8YFLogxK

U2 - 10.1111/bjh.14448

DO - 10.1111/bjh.14448

M3 - Article

VL - 176

SP - 950

EP - 960

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 6

ER -